ID   CBLB_HUMAN              Reviewed;         982 AA.
AC   Q13191; A8K9S7; B7WNM4; Q13192; Q13193; Q3LIC0; Q63Z43; Q8IVC5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   07-FEB-2006, sequence version 2.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL-B;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene b;
DE   AltName: Full=RING finger protein 56;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL-B {ECO:0000305};
DE   AltName: Full=SH3-binding protein CBL-B;
DE   AltName: Full=Signal transduction protein CBL-B;
GN   Name=CBLB; Synonyms=RNF56; ORFNames=Nbla00127;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG; TRUNCATED 1 AND TRUNCATED
RP   2).
RX   PubMed=7784085;
RA   Keane M.M., Rivero-Lezcano O.M., Mitchell J.A., Robbins K.C.,
RA   Lipkowitz S.;
RT   "Cloning and characterization of cbl-b: a SH3 binding protein with
RT   homology to the c-cbl proto-oncogene.";
RL   Oncogene 10:2367-2377(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), TISSUE SPECIFICITY, AND
RP   INTERACTION WITH VAV1.
RX   PubMed=9399639; DOI=10.1038/sj.onc.1201430;
RA   Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., Barbacid M.;
RT   "Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-
RT   mediated c-Jun N-terminal kinase activation.";
RL   Oncogene 15:2511-2520(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RA   Shen C.-R., Chen Y.-J., Pai L.-M., Liu C.-L.;
RT   "Cbl-b in Taiwan population.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT
RP   LYS-584.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 543-982 (ISOFORM LONG).
RC   TISSUE=Neuroblastoma;
RX   PubMed=12880961; DOI=10.1016/S0304-3835(03)00085-5;
RA   Ohira M., Morohashi A., Nakamura Y., Isogai E., Furuya K., Hamano S.,
RA   Machida T., Aoyama M., Fukumura M., Miyazaki K., Suzuki Y., Sugano S.,
RA   Hirato J., Nakagawara A.;
RT   "Neuroblastoma oligo-capping cDNA project: toward the understanding of
RT   the genesis and biology of neuroblastoma.";
RL   Cancer Lett. 197:63-68(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 857-982 (ISOFORM LONG).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   TISSUE SPECIFICITY, MUTAGENESIS OF GLY-298; TYR-665 AND TYR-709,
RP   INTERACTION WITH GRB2 AND CRKL, PHOSPHORYLATION AT TYR-665 AND
RP   TYR-709, AND FUNCTION.
RX   PubMed=10022120; DOI=10.1038/sj.onc.1202411;
RA   Elly C., Witte S., Zhang Z., Rosnet O., Lipkowitz S., Altman A.,
RA   Liu Y.-C.;
RT   "Tyrosine phosphorylation and complex formation of Cbl-b upon T cell
RT   receptor stimulation.";
RL   Oncogene 18:1147-1156(1999).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH GRB2 AND PIK3R1.
RX   PubMed=10086340; DOI=10.1038/sj.onc.1202499;
RA   Ettenberg S.A., Keane M.M., Nau M.M., Frankel M., Wang L.-M.,
RA   Pierce J.H., Lipkowitz S.;
RT   "cbl-b inhibits epidermal growth factor receptor signaling.";
RL   Oncogene 18:1855-1866(1999).
RN   [12]
RP   FUNCTION, INTERACTION WITH PIK3R1, AND MUTAGENESIS OF GLY-298 AND
RP   CYS-373.
RX   PubMed=11087752; DOI=10.1074/jbc.M008901200;
RA   Fang D., Wang H.-Y., Fang N., Altman Y., Elly C., Liu Y.-C.;
RT   "Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol
RT   3-kinase for ubiquitination in T cells.";
RL   J. Biol. Chem. 276:4872-4878(2001).
RN   [13]
RP   UBIQUITINATION, AND MUTAGENESIS OF CYS-373.
RX   PubMed=11375397; DOI=10.1074/jbc.M102641200;
RA   Ettenberg S.A., Magnifico A., Cuello M., Nau M.M., Rubinstein Y.R.,
RA   Yarden Y., Weissman A.M., Lipkowitz S.;
RT   "Cbl-b-dependent coordinated degradation of the epidermal growth
RT   factor receptor signaling complex.";
RL   J. Biol. Chem. 276:27677-27684(2001).
RN   [14]
RP   FUNCTION.
RX   PubMed=11526404; DOI=10.1038/ni0901-870;
RA   Fang D., Liu Y.-C.;
RT   "Proteolysis-independent regulation of PI3K by Cbl-b-mediated
RT   ubiquitination in T cells.";
RL   Nat. Immunol. 2:870-875(2001).
RN   [15]
RP   INTERACTION WITH SH3KBP1, AND SUBCELLULAR LOCATION.
RX   PubMed=12177062; DOI=10.1074/jbc.M205535200;
RA   Szymkiewicz I., Kowanetz K., Soubeyran P., Dinarina A., Lipkowitz S.,
RA   Dikic I.;
RT   "CIN85 participates in Cbl-b-mediated down-regulation of receptor
RT   tyrosine kinases.";
RL   J. Biol. Chem. 277:39666-39672(2002).
RN   [16]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [17]
RP   INTERACTION WITH UBIQUITINATED PROTEINS, AND MUTAGENESIS OF
RP   943-GLY-TYR-944 AND LEU-967.
RX   PubMed=15273720; DOI=10.1038/sj.onc.1207952;
RA   Davies G.C., Ettenberg S.A., Coats A.O., Mussante M., Ravichandran S.,
RA   Collins J., Nau M.M., Lipkowitz S.;
RT   "Cbl-b interacts with ubiquitinated proteins; differential functions
RT   of the UBA domains of c-Cbl and Cbl-b.";
RL   Oncogene 23:7104-7115(2004).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-521; SER-525 AND
RP   SER-529, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   PHOSPHORYLATION AT SER-282.
RX   PubMed=19549985; DOI=10.1126/scisignal.2000046;
RA   Gruber T., Hermann-Kleiter N., Hinterleitner R., Fresser F.,
RA   Schneider R., Gastl G., Penninger J.M., Baier G.;
RT   "PKC-theta modulates the strength of T cell responses by targeting
RT   Cbl-b for ubiquitination and degradation.";
RL   Sci. Signal. 2:RA30-RA30(2009).
RN   [21]
RP   FUNCTION AS E3 UBIQUITIN-PROTEIN LIGASE, CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION AT TYR-363, AND MUTAGENESIS OF TYR-363.
RX   PubMed=20525694; DOI=10.1074/jbc.M109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by
RT   modulating affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 899-914 IN COMPLEXES WITH
RP   SH3KBP1 AND ARHGEF7, MUTAGENESIS OF ARG-904 AND ARG-911, AND SUBUNIT.
RX   PubMed=16228008; DOI=10.1038/nsmb1000;
RA   Jozic D., Cardenes N., Deribe Y.L., Moncalian G., Hoeller D.,
RA   Groemping Y., Dikic I., Rittinger K., Bravo J.;
RT   "Cbl promotes clustering of endocytic adaptor proteins.";
RL   Nat. Struct. Mol. Biol. 12:972-979(2005).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 902-912 IN COMPLEX WITH
RP   CD2AP, MUTAGENESIS OF ARG-904; LYS-907 AND ARG-911, AND SUBUNIT.
RX   PubMed=17020880; DOI=10.1074/jbc.M606411200;
RA   Moncalian G., Cardenes N., Deribe Y.L., Spinola-Amilibia M., Dikic I.,
RA   Bravo J.;
RT   "Atypical polyproline recognition by the CMS N-terminal Src homology 3
RT   domain.";
RL   J. Biol. Chem. 281:38845-38853(2006).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) OF 924-973 IN COMPLEX WITH
RP   UBIQUITIN, STRUCTURE BY NMR OF 924-973, TYROSINE PHOSPHORYLATION, AND
RP   MUTAGENESIS OF ALA-937; MET-940; PHE-946 AND ILE-966.
RX   PubMed=17679095; DOI=10.1016/j.molcel.2007.06.023;
RA   Peschard P., Kozlov G., Lin T., Mirza I.A., Berghuis A.M.,
RA   Lipkowitz S., Park M., Gehring K.;
RT   "Structural basis for ubiquitin-mediated dimerization and activation
RT   of the ubiquitin protein ligase Cbl-b.";
RL   Mol. Cell 27:474-485(2007).
RN   [25]
RP   STRUCTURE BY NMR OF 931-970.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-065, a UBA domain from human cDNA.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-344 IN COMPLEX WITH
RP   PHOSPHO-EGFR PEPTIDE, INTERACTION WITH EGFR, AND HETERODIMER.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069
RT   peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       specific E2 ubiquitin-conjugating enzymes, and transfers it to
CC       substrates, generally promoting their degradation by the
CC       proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-
CC       cell receptor) and FCER1 (high affinity immunoglobulin epsilon
CC       receptor) signal transduction pathways. In naive T-cells, inhibits
CC       VAV1 activation upon TCR engagement and imposes a requirement for
CC       CD28 costimulation for proliferation and IL-2 production. Also
CC       acts by promoting PIK3R1/p85 ubiquitination, which impairs its
CC       recruitment to the TCR and subsequent activation. In activated T-
CC       cells, inhibits PLCG1 activation and calcium mobilization upon
CC       restimulation and promotes anergy. In B-cells, acts by
CC       ubiquitinating SYK and promoting its proteasomal degradation.
CC       Slightly promotes SRC ubiquitination. May be involved in EGFR
CC       ubiquitination and internalization. May be functionally coupled
CC       with the E2 ubiquitin-protein ligase UB2D3.
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:11087752, ECO:0000269|PubMed:11526404,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:20525694}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with SH3 domain-containing proteins LCK, CRK
CC       and SORBS1. Interacts with LCP2 and ZAP70. May interact with CBL.
CC       Interacts with SH3 domain-containing proteins VAV1, FYN, FGR,
CC       PLCG1, GRB2, CRKL, PIK3R1 and SH3KBP1/CIN85. Identified in
CC       heterotrimeric complexes with SH3KBP1/CIN85, CD2AP and ARHGEF7,
CC       where one CBLB peptide binds two copies of the other protein.
CC       Interacts with poly-ubiquitinated proteins. Dimerization is
CC       required for the binding of poly-ubiquitin, but not for the
CC       binding of mono-ubiquitin. Interacts with EGFR (phosphorylated).
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:11087752, ECO:0000269|PubMed:12177062,
CC       ECO:0000269|PubMed:15273720, ECO:0000269|PubMed:16228008,
CC       ECO:0000269|PubMed:17020880, ECO:0000269|PubMed:17679095,
CC       ECO:0000269|PubMed:9399639, ECO:0000269|Ref.26}.
CC   -!- INTERACTION:
CC       Q9ULH1:ASAP1; NbExp=2; IntAct=EBI-744027, EBI-346622;
CC       Q9Y5K6:CD2AP; NbExp=11; IntAct=EBI-744027, EBI-298152;
CC       P46108:CRK; NbExp=4; IntAct=EBI-744027, EBI-886;
CC       P46109:CRKL; NbExp=4; IntAct=EBI-744027, EBI-910;
CC       P06241-3:FYN; NbExp=3; IntAct=EBI-744027, EBI-10691738;
CC       O76003:GLRX3; NbExp=3; IntAct=EBI-744027, EBI-374781;
CC       Q9H8Y8:GORASP2; NbExp=6; IntAct=EBI-744027, EBI-739467;
CC       P62993:GRB2; NbExp=10; IntAct=EBI-744027, EBI-401755;
CC       P16333:NCK1; NbExp=4; IntAct=EBI-744027, EBI-389883;
CC       O43639:NCK2; NbExp=4; IntAct=EBI-744027, EBI-713635;
CC       Q96B97:SH3KBP1; NbExp=21; IntAct=EBI-744027, EBI-346595;
CC       Q8TF42:UBASH3B; NbExp=5; IntAct=EBI-744027, EBI-1380492;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12177062}.
CC       Note=Upon EGF stimulation, associates with endocytic vesicles.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=Q13191-1; Sequence=Displayed;
CC       Name=Truncated 1;
CC         IsoId=Q13191-2; Sequence=VSP_005729;
CC       Name=Truncated 2;
CC         IsoId=Q13191-3; Sequence=VSP_005730, VSP_005731;
CC   -!- TISSUE SPECIFICITY: Expressed in placenta, heart, lung, kidney,
CC       spleen, ovary and testis, as well as fetal brain and liver and
CC       hematopoietic cell lines, but not in adult brain, liver, pancreas,
CC       salivary gland, or skeletal muscle. Present in lymphocytes (at
CC       protein level). {ECO:0000269|PubMed:10022120,
CC       ECO:0000269|PubMed:9399639}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC       (PTB) domain, a short linker region and the RING-type zinc finger.
CC       The PTB domain, which is also called TKB (tyrosine kinase binding)
CC       domain, is composed of three different subdomains: a four-helix
CC       bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme.
CC   -!- DOMAIN: The UBA domain interacts with poly-ubiquitinated proteins.
CC   -!- PTM: Phosphorylated on tyrosine and serine residues upon TCR or
CC       BCR activation, and upon various types of cell stimulation.
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:19549985, ECO:0000269|PubMed:20525694}.
CC   -!- PTM: Auto-ubiquitinated upon EGF-mediated cell activation or upon
CC       T-cell costimulation by CD28; which promotes proteasomal
CC       degradation. {ECO:0000269|PubMed:11375397}.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding
CC       site. {ECO:0000250}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE45748.1; Type=Erroneous termination; Positions=904; Note=Translated as Arg.; Evidence={ECO:0000305};
CC       Sequence=CAH56175.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLbID193.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U26710; AAB09291.1; -; mRNA.
DR   EMBL; U26711; AAB09292.1; -; mRNA.
DR   EMBL; U26712; AAB09293.1; -; mRNA.
DR   EMBL; DQ349203; ABC86700.1; -; mRNA.
DR   EMBL; AK292792; BAF85481.1; -; mRNA.
DR   EMBL; AC016138; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79752.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79753.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79754.1; -; Genomic_DNA.
DR   EMBL; BC032851; AAH32851.1; -; mRNA.
DR   EMBL; AB075490; BAE45748.1; ALT_SEQ; mRNA.
DR   EMBL; BX537484; CAH56175.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS2948.1; -. [Q13191-1]
DR   RefSeq; NP_001308717.1; NM_001321788.1. [Q13191-1]
DR   RefSeq; NP_733762.2; NM_170662.4. [Q13191-1]
DR   RefSeq; XP_011511559.1; XM_011513257.1. [Q13191-1]
DR   UniGene; Hs.430589; -.
DR   PDB; 2AK5; X-ray; 1.85 A; D=904-911.
DR   PDB; 2BZ8; X-ray; 2.00 A; C=902-912.
DR   PDB; 2DO6; NMR; -; A/B=931-970.
DR   PDB; 2J6F; X-ray; 1.70 A; C=902-912.
DR   PDB; 2JNH; NMR; -; A=926-971.
DR   PDB; 2LDR; NMR; -; A=351-426.
DR   PDB; 2OOA; X-ray; 1.56 A; A/B=924-973.
DR   PDB; 2OOB; X-ray; 1.90 A; A=924-973.
DR   PDB; 3PFV; X-ray; 2.27 A; A/B=38-344.
DR   PDB; 3VGO; X-ray; 3.10 A; A/B/C=39-426.
DR   PDB; 3ZNI; X-ray; 2.21 A; A/E/I/M=36-427.
DR   PDBsum; 2AK5; -.
DR   PDBsum; 2BZ8; -.
DR   PDBsum; 2DO6; -.
DR   PDBsum; 2J6F; -.
DR   PDBsum; 2JNH; -.
DR   PDBsum; 2LDR; -.
DR   PDBsum; 2OOA; -.
DR   PDBsum; 2OOB; -.
DR   PDBsum; 3PFV; -.
DR   PDBsum; 3VGO; -.
DR   PDBsum; 3ZNI; -.
DR   ProteinModelPortal; Q13191; -.
DR   SMR; Q13191; -.
DR   BioGrid; 107316; 59.
DR   DIP; DIP-33091N; -.
DR   IntAct; Q13191; 37.
DR   MINT; MINT-256380; -.
DR   STRING; 9606.ENSP00000264122; -.
DR   iPTMnet; Q13191; -.
DR   PhosphoSitePlus; Q13191; -.
DR   BioMuta; CBLB; -.
DR   DMDM; 88911265; -.
DR   EPD; Q13191; -.
DR   MaxQB; Q13191; -.
DR   PaxDb; Q13191; -.
DR   PeptideAtlas; Q13191; -.
DR   PRIDE; Q13191; -.
DR   DNASU; 868; -.
DR   Ensembl; ENST00000264122; ENSP00000264122; ENSG00000114423. [Q13191-1]
DR   Ensembl; ENST00000403724; ENSP00000384816; ENSG00000114423. [Q13191-3]
DR   GeneID; 868; -.
DR   KEGG; hsa:868; -.
DR   UCSC; uc003dwc.4; human. [Q13191-1]
DR   CTD; 868; -.
DR   DisGeNET; 868; -.
DR   GeneCards; CBLB; -.
DR   H-InvDB; HIX0003518; -.
DR   HGNC; HGNC:1542; CBLB.
DR   HPA; HPA018327; -.
DR   HPA; HPA019880; -.
DR   MIM; 604491; gene.
DR   neXtProt; NX_Q13191; -.
DR   OpenTargets; ENSG00000114423; -.
DR   PharmGKB; PA26116; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00390000011617; -.
DR   HOVERGEN; HBG005255; -.
DR   InParanoid; Q13191; -.
DR   KO; K04707; -.
DR   OMA; CCSIIDP; -.
DR   OrthoDB; EOG091G0GPE; -.
DR   PhylomeDB; Q13191; -.
DR   TreeFam; TF314210; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q13191; -.
DR   SIGNOR; Q13191; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; CBLB; human.
DR   EvolutionaryTrace; Q13191; -.
DR   GeneWiki; CBLB_(gene); -.
DR   GenomeRNAi; 868; -.
DR   PRO; PR:Q13191; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114423; -.
DR   CleanEx; HS_CBLB; -.
DR   ExpressionAtlas; Q13191; baseline and differential.
DR   Genevisible; Q13191; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0001784; F:phosphotyrosine binding; IEA:InterPro.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IBA:GO_Central.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0006607; P:NLS-bearing protein import into nucleus; TAS:ProtInc.
DR   GO; GO:0006508; P:proteolysis; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd00162; RING; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Cytoplasm; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    982       E3 ubiquitin-protein ligase CBL-B.
FT                                /FTId=PRO_0000055860.
FT   DOMAIN       35    343       Cbl-PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00839}.
FT   DOMAIN      931    970       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   CA_BIND     219    232       {ECO:0000255|PROSITE-ProRule:PRU00839}.
FT   ZN_FING     373    412       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION       35    167       4H.
FT   REGION      168    240       EF-hand-like.
FT   REGION      241    343       SH2-like.
FT   REGION      344    372       Linker.
FT   REGION      543    568       Interaction with VAV1.
FT                                {ECO:0000269|PubMed:9399639}.
FT   REGION      891    927       Interaction with SH3KBP1.
FT                                {ECO:0000269|PubMed:12177062}.
FT   COMPBIAS    477    925       Pro-rich.
FT   BINDING     286    286       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     282    282       Phosphoserine; by PKC/PRKCQ.
FT                                {ECO:0000269|PubMed:19549985}.
FT   MOD_RES     363    363       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:20525694}.
FT   MOD_RES     476    476       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8K4S7}.
FT   MOD_RES     480    480       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q3TTA7}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q3TTA7}.
FT   MOD_RES     521    521       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     525    525       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     529    529       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     634    634       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8K4S7}.
FT   MOD_RES     665    665       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10022120}.
FT   MOD_RES     709    709       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10022120}.
FT   MOD_RES     889    889       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q3TTA7}.
FT   VAR_SEQ     767    770       DVFD -> TYRI (in isoform Truncated 2).
FT                                {ECO:0000303|PubMed:7784085}.
FT                                /FTId=VSP_005730.
FT   VAR_SEQ     771    982       Missing (in isoform Truncated 2).
FT                                {ECO:0000303|PubMed:7784085}.
FT                                /FTId=VSP_005731.
FT   VAR_SEQ     811    982       Missing (in isoform Truncated 1).
FT                                {ECO:0000303|PubMed:7784085}.
FT                                /FTId=VSP_005729.
FT   VARIANT     584    584       R -> K (in dbSNP:rs17853100).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_025303.
FT   VARIANT     883    883       N -> D (in dbSNP:rs35835913).
FT                                /FTId=VAR_039241.
FT   MUTAGEN     298    298       G->E: Inhibits interaction with SYK. No
FT                                effect on E3 activity.
FT                                {ECO:0000269|PubMed:10022120,
FT                                ECO:0000269|PubMed:11087752}.
FT   MUTAGEN     363    363       Y->E: Decreases affinity for E2
FT                                ubiquitin-conjugating enzymes.
FT                                {ECO:0000269|PubMed:20525694}.
FT   MUTAGEN     373    373       C->A: Abolishes E3 activity but does not
FT                                affect binding to substrates.
FT                                {ECO:0000269|PubMed:11087752,
FT                                ECO:0000269|PubMed:11375397}.
FT   MUTAGEN     665    665       Y->F: Slightly inhibits interaction with
FT                                CRKL. Abolishes interaction with CRKL;
FT                                when associated with F-709.
FT                                {ECO:0000269|PubMed:10022120}.
FT   MUTAGEN     709    709       Y->F: Inhibits interaction with CRKL.
FT                                Abolishes interaction with CRKL; when
FT                                associated with F-665.
FT                                {ECO:0000269|PubMed:10022120}.
FT   MUTAGEN     904    904       R->A: No effect on interaction with
FT                                CD2AP. Reduced interaction with SH3KBP1.
FT                                Strongly reduced interaction with
FT                                SH3KBP1; when associated with A-911.
FT                                {ECO:0000269|PubMed:16228008,
FT                                ECO:0000269|PubMed:17020880}.
FT   MUTAGEN     907    907       K->A: No effect on interaction with
FT                                SH3KBP1. Reduced interaction with CD2AP.
FT                                Strongly reduced interaction with CD2AP;
FT                                when associated with A-911.
FT                                {ECO:0000269|PubMed:17020880}.
FT   MUTAGEN     911    911       R->A: Reduced interaction with CD2AP and
FT                                with SH3KBP1. Strongly reduced
FT                                interaction with CD2AP; when associated
FT                                with A-907. Strongly reduced interaction
FT                                with SH3KBP1; when associated with A-904.
FT                                {ECO:0000269|PubMed:16228008,
FT                                ECO:0000269|PubMed:17020880}.
FT   MUTAGEN     937    937       A->E: Loss of ubiquitin binding. Reduced
FT                                levels of tyrosine phosphorylation.
FT                                {ECO:0000269|PubMed:17679095}.
FT   MUTAGEN     940    940       M->A: Loss of ubiquitin binding. Reduced
FT                                levels of tyrosine phosphorylation.
FT                                {ECO:0000269|PubMed:17679095}.
FT   MUTAGEN     943    944       GY->AQ: Abolishes interaction with
FT                                ubiquitinated proteins.
FT                                {ECO:0000269|PubMed:15273720}.
FT   MUTAGEN     946    946       F->A: Loss of ubiquitin binding. Reduced
FT                                levels of tyrosine phosphorylation.
FT                                {ECO:0000269|PubMed:17679095}.
FT   MUTAGEN     966    966       I->E: Interferes with dimerization.
FT                                Reduced E3 ubiquitin-protein ligase
FT                                activity. Reduced levels of tyrosine
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:17679095}.
FT   MUTAGEN     967    967       L->A: No effect on interaction with
FT                                ubiquitinated proteins.
FT                                {ECO:0000269|PubMed:15273720}.
FT   CONFLICT    210    210       G -> S (in Ref. 1; AAB09291/AAB09292/
FT                                AAB09293). {ECO:0000305}.
FT   CONFLICT    911    911       R -> C (in Ref. 9; CAH56175).
FT                                {ECO:0000305}.
FT   HELIX        43     60       {ECO:0000244|PDB:3ZNI}.
FT   HELIX        63     65       {ECO:0000244|PDB:3ZNI}.
FT   STRAND       69     72       {ECO:0000244|PDB:3ZNI}.
FT   HELIX        74     91       {ECO:0000244|PDB:3ZNI}.
FT   HELIX        95    102       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       105    128       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       129    133       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       138    160       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       162    164       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       168    170       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       176    186       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      190    193       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       194    204       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       210    220       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      225    229       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       230    239       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       243    245       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       246    253       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      260    263       {ECO:0000244|PDB:3VGO}.
FT   HELIX       266    273       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       274    276       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      282    287       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      289    291       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      295    300       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      306    309       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      312    314       {ECO:0000244|PDB:3PFV}.
FT   HELIX       316    325       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       332    334       {ECO:0000244|PDB:3VGO}.
FT   HELIX       342    344       {ECO:0000244|PDB:3PFV}.
FT   STRAND      352    354       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       357    364       {ECO:0000244|PDB:3ZNI}.
FT   TURN        365    367       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      370    372       {ECO:0000244|PDB:3ZNI}.
FT   TURN        374    376       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      377    380       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      383    386       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       394    402       {ECO:0000244|PDB:3ZNI}.
FT   TURN        409    411       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      417    420       {ECO:0000244|PDB:3ZNI}.
FT   STRAND      422    424       {ECO:0000244|PDB:3ZNI}.
FT   HELIX       933    941       {ECO:0000244|PDB:2OOA}.
FT   HELIX       946    955       {ECO:0000244|PDB:2OOA}.
FT   TURN        956    958       {ECO:0000244|PDB:2OOA}.
FT   HELIX       960    970       {ECO:0000244|PDB:2OOA}.
SQ   SEQUENCE   982 AA;  109450 MW;  B4E307D31B9F0779 CRC64;
     MANSMNGRNP GGRGGNPRKG RILGIIDAIQ DAVGPPKQAA ADRRTVEKTW KLMDKVVRLC
     QNPKLQLKNS PPYILDILPD TYQHLRLILS KYDDNQKLAQ LSENEYFKIY IDSLMKKSKR
     AIRLFKEGKE RMYEEQSQDR RNLTKLSLIF SHMLAEIKAI FPNGQFQGDN FRITKADAAE
     FWRKFFGDKT IVPWKVFRQC LHEVHQISSG LEAMALKSTI DLTCNDYISV FEFDIFTRLF
     QPWGSILRNW NFLAVTHPGY MAFLTYDEVK ARLQKYSTKP GSYIFRLSCT RLGQWAIGYV
     TGDGNILQTI PHNKPLFQAL IDGSREGFYL YPDGRSYNPD LTGLCEPTPH DHIKVTQEQY
     ELYCEMGSTF QLCKICAEND KDVKIEPCGH LMCTSCLTAW QESDGQGCPF CRCEIKGTEP
     IIVDPFDPRD EGSRCCSIID PFGMPMLDLD DDDDREESLM MNRLANVRKC TDRQNSPVTS
     PGSSPLAQRR KPQPDPLQIP HLSLPPVPPR LDLIQKGIVR SPCGSPTGSP KSSPCMVRKQ
     DKPLPAPPPP LRDPPPPPPE RPPPIPPDNR LSRHIHHVES VPSRDPPMPL EAWCPRDVFG
     TNQLVGCRLL GEGSPKPGIT ASSNVNGRHS RVGSDPVLMR KHRRHDLPLE GAKVFSNGHL
     GSEEYDVPPR LSPPPPVTTL LPSIKCTGPL ANSLSEKTRD PVEEDDDEYK IPSSHPVSLN
     SQPSHCHNVK PPVRSCDNGH CMLNGTHGPS SEKKSNIPDL SIYLKGDVFD SASDPVPLPP
     ARPPTRDNPK HGSSLNRTPS DYDLLIPPLG EDAFDALPPS LPPPPPPARH SLIEHSKPPG
     SSSRPSSGQD LFLLPSDPFV DLASGQVPLP PARRLPGENV KTNRTSQDYD QLPSCSDGSQ
     APARPPKPRP RRTAPEIHHR KPHGPEAALE NVDAKIAKLM GEGYAFEEVK RALEIAQNNV
     EVARSILREF AFPPPVSPRL NL
//
